Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 40

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 40
---
 We successfully completed several Merger integration activities, including holding a successful Special Meeting of Stockholders in March 2024, (the “March 2024 Special Meeting”) at which stockholders approved the conversion of Series A Preferred Stock to Common Stock.

• In March 2024, we announced the establishment of a new, state-of-the-art, approximately 20,000 square foot cell therapy cGMP manufacturing facility in Frederick, Maryland. All material company operations were transitioned to this facility as of October 2024, and we have since expanded our occupied space in the building to include over 29,000 square feet as of December 31, 2024.

• In May 2024, we announced that the FDA had granted Regenerative Medicine Advanced Therapy (“RMAT”) designation for our Descartes-08 product candidate for the treatment of MG. Receiving RMAT designation offers sponsor companies the benefits of the fast track and breakthrough therapy designation programs with the goal of expediting drug development. Subsequently, in September 2024, we announced that the FDA had granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (“JDM”). Under the FDA’s Rare Pediatric Disease Designation and Voucher Program, if Descartes-08 is approved for marketing in JDM, Cartesian may qualify for a priority review voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product.

• In July, October and December 2024, we announced positive results from our Phase 2b trial of Descartes-08 in patients with generalized MG with deepening responses observed over time that were sustained through 12 months. We also announced the dosing of the first patient in our Phase 2 open-label clinical trial evaluating Descartes-08 in patients with systematic lupus erythematosus, and the dosing of the first patient in our first-in-human Phase 1 trial of Descartes-15 in patients with multiple myeloma.

• In July 2024, we announced a private placement in public equity financing resulting in gross proceeds of $130 million. We then held a successful Special Meeting of Stockholders in September 2024, at which stockholders approved the conversion of Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”), issued in the July 2024 financing to Common Stock.

<div align='center'>24</div>

#### 2024 Executive